Direct CXCR4 antagonists, including AMD3100(Plerixafor), AMD070, and WKI, demonstrated a pro-apoptotic effect in CXCR4 + DLBCL cells via modulation of JNK, ERK, NF-κB/ BCR, and BCL2 targets [176]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.